Tiny study checks if HIV meds in pregnancy alter Baby's immune system
NCT ID NCT04024150
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 29 newborns to see if exposure to a class of HIV drugs called anti-integrases (like raltegravir) in the womb affects their immune system at birth. Researchers compared these babies to those exposed to other HIV medications. The goal was to check the diversity of T cells, a key part of the immune system, using a single blood sample taken at birth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- anti-integrase antiretroviral drugs (raltegravir, elvitegravir, dolutegravir, bictegravir)
- What this could lead to
- If successful, this could help doctors understand whether certain HIV medications are safer for the baby's developing immune system during pregnancy.
- What could go wrong
- This is a very small, completed observational study with only 29 newborns, so results may not apply broadly. It measures immune markers at birth, not long-term health outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTI-INTEGRASES are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AP-HP, Hôpital Bichat-Claude Bernard
Paris, 75018, France
-
AP-HP, Hôpital Cochin
Paris, 75014, France
-
AP-HP, Hôpital Louis Mourier
Colombes, 92700, France
-
AP-HP, Hôpital Necker
Paris, 75015, France
-
AP-HP, Hôpital de la Pitié Salpêtrière
Paris, 75013, France